ArticleBlood2016

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

Paul G Richardson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.